Insider sale notices at Mineralys Therapeutics (NASDAQ: MLYS) detail multiple Q1 2026 transactions
Rhea-AI Filing Summary
Mineralys Therapeutics filed a Form 144 reporting proposed transactions in its common stock. The filing lists a broker-assisted cashless exercise of 417 shares on 03/17/2026 and a series of prior dispositions by David Rodman during Q1 2026, including a 192,715-share sale on 01/05/2026 for $6,749,100.06. The entries are presented as notices of securities to be sold and past sales by an affiliate.
Positive
- None.
Negative
- None.
Insights
Form 144 lists a small exercise and multiple past sales by a reporting person.
The filing documents a broker-assisted cashless exercise of 417 shares on 03/17/2026 and multiple dispositions by David Rodman across January–March 2026, with the largest shown sale of 192,715 shares on 01/05/2026 for $6,749,100.06.
These entries are regulatory notices of proposed or recent sales; trading timing and further cash‑flow details follow standard Form 144 reporting procedures and may be reflected in subsequent ownership disclosures.